
Adalimumab Biosimilars Demonstrate Long-Term Durability and Cost-Effectiveness in Paediatric Inflammatory Bowel Disease: ...
Introduction The treatment of Inflammatory Bowel Disease (IBD) has radically changed over the past few decades, driven by significant advances in the understanding of its pathogenesis and the development of targeted therapies, particularly biologic agents. …